Friday February 24th 2017: Allergan plc, AGN is in the exchange NYSE and its industry is Drugs – Generic in the sector of Healthcare. Based in USA, Allergan plc, AGN has a market cap of 83.42 B. Since its IPO date on the 2/17/1993, Allergan plc, AGN performance year to date is 16.94%. Today Allergan plc, AGN has gained -0.76%, with a current price of 243.72.
Ownership of the company is 0.20% for insider ownership while institutional ownership is 87.80%. The management of the company have seen the company have a payout ratio of 2.40%. Return of assets are at 8.90%, with return on investment at 0.10%.
In terms of debt levels and profit levels, Allergan plc, AGN is seeing a long-term debt/equity of 0.37. While Total debt/equity is 0.45. With a profit margin of 80.50%, this is combined with a gross margin of 87.60%, and operating margin of -17.40%. Allergan plc ability to meet debt levels, with a current ratio of 1.3, while the quick ratio is 1.2.
For the last year Allergan plc, AGN has seen a EPS growth of 63.30%. A performance for the year of 2.46%. The 52-week high is -6.72%, and the 52-week low is 32.10%. The average volume for Allergan plc, AGN is 482237.
With a target price of 272.44, can Allergan plc, AGN reach this target? Looking at the value indicators of Allergan plc, AGN. Allergan plc has a P/E of *TBA and a forward P/E of 13.7. Perhaps the more useful indicator than P/E, is PEG which has a value of *TBA. Allergan plc also has a P/S and a P/B of 5.66 and 1.17 respectively. For P/cash, Allergan plc has a value of 9.32, while it is *TBA for P/free cash flow.
At the current price of 243.72, Allergan plc has a dividend yield of 1.14%. We see a return on equity of 15.90%.
Looking more long-term Allergan plc, is projected to get an EPS growth for the next five years of 13.10%. In the short-term an EPS growth of 11.39% in the next year is forecasted. This is after a EPS growth of 63.30% for this year and for the last five years a -28.70% growth has been seen.